PL438343A1 - Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo-4'-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu - Google Patents

Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo-4'-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu

Info

Publication number
PL438343A1
PL438343A1 PL438343A PL43834321A PL438343A1 PL 438343 A1 PL438343 A1 PL 438343A1 PL 438343 A PL438343 A PL 438343A PL 43834321 A PL43834321 A PL 43834321A PL 438343 A1 PL438343 A1 PL 438343A1
Authority
PL
Poland
Prior art keywords
sub
cancer
prevention
treatment
isoselenocyanatobutyl
Prior art date
Application number
PL438343A
Other languages
English (en)
Other versions
PL246985B1 (pl
Inventor
Tomasz Cierpiał
Piotr Kiełbasiński
Milena MAŁECKA-GIEŁDOWSKA
Maciej Mazur
Małgorzata Milczarek
Katarzyna WIKTORSKA
Original Assignee
Uniwersytet Warszawski
Narodowy Instytut Leków
Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski, Narodowy Instytut Leków, Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk, Warszawski Uniwersytet Medyczny filed Critical Uniwersytet Warszawski
Priority to PL438343A priority Critical patent/PL246985B1/pl
Priority to PCT/PL2022/050042 priority patent/WO2023277717A1/en
Publication of PL438343A1 publication Critical patent/PL438343A1/pl
Publication of PL246985B1 publication Critical patent/PL246985B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest kombinacja zawierająca: fluorowany izoselenocyjanian o wzorze ogólnym: w którym Ar<sub>F</sub> oznacza grupę polifluoroarylową o wzorze C<sub>6</sub>H<sub>k</sub>(CF<sub>3</sub>)F<sub>5-k-p</sub>, gdzie k oznacza liczbę naturalną od 0 do 4, p oznacza liczbę 0, 1 lub 2, x oznacza liczbę 0, 1 lub 2, z oznacza liczbę 0, 1 lub 2, a y oznacza liczbę naturalną od 3 do 6, oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu, przy czym lek przeciwnowotworowy wybiera się spośród: leków onkologicznych do terapii celowanych, inhibitorów mitozy, antybiotyków o działaniu cytostatycznym, antymetabolitów lub ich mieszaniny.
PL438343A 2021-07-02 2021-07-02 Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo- 4’-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu PL246985B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL438343A PL246985B1 (pl) 2021-07-02 2021-07-02 Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo- 4’-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu
PCT/PL2022/050042 WO2023277717A1 (en) 2021-07-02 2022-07-04 Combination containing fluorinated isoselenocyanates and anticancer drug for use in cancer prevention or treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438343A PL246985B1 (pl) 2021-07-02 2021-07-02 Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo- 4’-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu

Publications (2)

Publication Number Publication Date
PL438343A1 true PL438343A1 (pl) 2023-01-09
PL246985B1 PL246985B1 (pl) 2025-04-22

Family

ID=83398177

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438343A PL246985B1 (pl) 2021-07-02 2021-07-02 Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo- 4’-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu

Country Status (2)

Country Link
PL (1) PL246985B1 (pl)
WO (1) WO2023277717A1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL235779B1 (pl) * 2015-10-27 2020-10-19 Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk Nowe analogi sulforafanu, ich prekursory, sposób ich wytwarzania oraz zastosowanie

Also Published As

Publication number Publication date
WO2023277717A1 (en) 2023-01-05
PL246985B1 (pl) 2025-04-22

Similar Documents

Publication Publication Date Title
Pud et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial
Kraychete et al. Postoperative persistent chronic pain: what do we know about prevention, risk factors, and treatment
Fiorica et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix
Magnowska et al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
PT1307197E (pt) Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
ECSP055680A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
Wedmore et al. Pain management in the wilderness and operational setting
CN101965192A (zh) 改善的抗肿瘤治疗
RU2009146008A (ru) Синергическая фармацевтическая комбинация для лечения рака
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
PL438343A1 (pl) Kombinacja zawierająca sulfotlenek 4-izoselenocyjanianobutylowo-4&#39;-fluorobenzylowy oraz lek przeciwnowotworowy do stosowania w zapobieganiu lub leczeniu nowotworu
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
CN103040859A (zh) 吸入的一氧化二氮或氙用于预防由癌症化疗引起的神经性疼痛的用途
BR112022009510A2 (pt) Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
BR0317519A (pt) Composição farmacêutica para anestesia local e uso da mesma
MX2025011086A (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
JP4865792B2 (ja) 局所麻酔薬の効果増強・時間延長剤